An observational study in Age Related Macular Degeneration, sponsored by Notal Vision Ltd.. Completed. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2010-09-23.
Sponsored by Notal Vision Ltd. · Observational
The purpose of this study is to evaluate the usability of the Foresee Home device with intermediate AMD patients.
The AMD usability study is a prospective, longitudinal, multi-center, observational study of patients diagnosed with intermediate (dry) AMD who have been asked by their doctor to use the ForeseeHomeTM device to record the natural progression of their AMD, including conversion from the dry to wet stage.
1,474 studies on the registry are indexed under Macular Degeneration; 206 are open to participants now.
This study's enrollment of 54 is below the median of 106 across 421 observational studies indexed under Macular Degeneration.
Browse Macular Degeneration studies →Notal Vision Ltd. is the lead sponsor of 25 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Intermediate AMD
Exclusion criteria
subjects diagnosed as intermediate AMD in at least one eye
Device: Foresee Home
Home Monitoring
Successful unpacking and installation
Time frame: 3 months
Successful self tutorial performance
Time frame: 3 months
Ability of the subjects to operate the device as define by a successful test completion
Time frame: 3 months
Evaluate the success rate of the interactive tutorial as defined by a reliable test result.
Time frame: 3 month
No study locations are listed for this record.
This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Notal Vision Ltd.